DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: bromocriptine mesylate

Summary for Generic Name: bromocriptine mesylate

Tradenames:3
Patents:8
Applicants:7
NDAs:8
Drug Master File Entries: see list9
Suppliers: see list3
Therapeutic Class:Antiparkinson Agents
Hormonal Agents, Suppressant (Pituitary)

Pharmacology for Ingredient: bromocriptine mesylate

Ingredient-typeErgolines
Drug ClassErgot Derivative

Clinical Trials for: bromocriptine mesylate

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects
Status: Recruiting Condition: Type 2 Diabetes

Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg
Status: Completed Condition: Healthy

Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets
Status: Completed Condition: Healthy

Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy
Status: Recruiting Condition: Peripartum Cardiomyopathy

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes Mellitus

Vaginal Bromocriptine for Treatment of Adenomyosis
Status: Recruiting Condition: Adenomyosis

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
Status: Recruiting Condition: Parkinson's Disease

Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study
Status: Not yet recruiting Condition: PCOS; Insulin Resistance

Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
Status: Terminated Condition: Graves Ophthalmopathy

QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
Status: Completed Condition: Diabetes Mellitus, Type 2

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Us Pharms Holdings I
PARLODEL
bromocriptine mesylate
TABLET;ORAL017962Approved Prior to Jan 1, 1982RXYes<disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866May 5, 2009RXYes5,679,685<disabled>Y
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866May 5, 2009RXYes8,137,994<disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866May 5, 2009RXYes8,137,992<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc